Hodgkins lymphoma

Researchers are testing whether adding abatacept to standard immune-suppressing drugs can prevent severe graft-versus-host disease after a double umbilical cord blood transplant. The trial enrolls people with blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes…

This study tests whether combining the drug pembrolizumab with a precise form of radiation can cure people with early-stage Hodgkin lymphoma that has returned or not responded to initial treatment. About 22 participants will receive this combination, with the goal of avoiding the…

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be life-threatening for people with weakened immune systems. The vaccine uses harmless virus pieces to train th…

This study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if giving these drugs alone or together can shrink tumors. The trial involves 13 adults with measu…

Researchers test a treatment plan for adults with Hodgkin lymphoma that has come back or stopped responding to initial therapy. Participants receive nivolumab, an immunotherapy, plus three chemotherapy drugs. PET scans help doctors decide how much treatment each person needs. The…

This study tests a personalized approach for people with early-stage Hodgkin lymphoma. Doctors use PET scans to decide if standard chemotherapy alone is enough or if adding immunotherapy drugs can improve results. The goal is to boost survival while limiting unnecessary treatment…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help children and young adults (ages 3-25) with newly diagnosed classical Hodgkin lymphoma who did not respond well to initial chemo. About 340 participants will receive pemb…

This study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…

This phase 2 trial tests whether adjusting treatment based on a very early PET scan can improve outcomes and reduce side effects for people with advanced Hodgkin lymphoma. Participants receive brentuximab vedotin plus chemotherapy, with the regimen modified according to how well …

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (BEGEV) helps people with Hodgkin's lymphoma that has returned or not responded to first treatment. About 122 adults aged 18-60 will receive the combination before a stem cell transplant.…

This early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-phase study tests a new approach for patients with certain lymphomas (Hodgkin, NK/T-cell, and others) that have returned or not responded to treatment. The therapy uses immune cells from healthy donors that are specially trained in the lab to attack cancer cells carryi…

This study tested a new treatment plan for people with Hodgkin lymphoma that returned or didn't respond to initial therapy. The approach combines an immunotherapy drug (nivolumab) with standard chemotherapy (ICE) to shrink the cancer before a stem cell transplant. The goal was to…

This phase 2 trial tests a combination of two targeted drugs (brentuximab vedotin and pembrolizumab) plus standard chemotherapy (doxorubicin and dacarbazine) in 25 people with untreated advanced Hodgkin lymphoma. The goal is to see if this approach is safe and effective. Particip…

This early-stage trial is testing whether a combination of tumor-specific immune cells (TAA-T) and the drug nivolumab can safely help people with lymphoma that has returned or not responded to treatment. Participants receive two infusions of TAA-T cells along with nivolumab, whic…

This study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…

This phase 3 trial compares two immunotherapy drugs—nivolumab (Opdivo) and brentuximab vedotin (Adcetris)—when added to standard chemotherapy for people aged 12 and older with newly diagnosed stage III or IV classic Hodgkin lymphoma. The goal is to see which combination better de…

This study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…

This study tests whether giving patients hyperbaric oxygen (breathing pure oxygen in a pressurized chamber) after an umbilical cord blood stem cell transplant helps the donated stem cells grow faster. The trial enrolls people with blood cancers like leukemia or lymphoma who lack …

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cell…

This phase 2 study is testing a risk-adapted approach for children and young adults with classical Hodgkin lymphoma. Depending on their risk level, patients receive different combinations of chemotherapy drugs, with the goal of improving response while reducing side effects. The …

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This phase 2 trial tests whether combining two drugs—nivolumab and axatilimab—can help people with classical Hodgkin lymphoma that has come back or not responded to prior treatments. The study includes 9 adults who have already tried at least one other therapy. Researchers will m…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This phase 2 trial is testing a shorter, more intense chemotherapy regimen called Stanford V in children and young adults with favorable Hodgkin lymphoma. Those who still have signs of cancer after 8 weeks of chemo also receive low-dose radiation to the affected areas. The goal i…

This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…

This phase 2 pilot study tests whether giving brentuximab vedotin weekly, alone or with nivolumab, can help people with CD30+ lymphoma whose cancer stopped responding to the standard every-3-week dosing. The study enrolls 28 adults with relapsed or refractory Hodgkin or non-Hodgk…

This phase II trial tests the safety and effectiveness of a drug called XmAb20717 in 140 people with advanced rare cancers, including mesothelioma, lymphoma, and small cell lung cancer. The drug is given by IV. The main goal is to see if tumors shrink. The trial is currently susp…

This study was designed to test a new treatment called CD30-targeted CAR-T cells for people with lymphoma (a type of blood cancer) that had returned or stopped responding to standard therapy. The treatment involved taking a patient's own immune cells, engineering them to recogniz…

This phase 2 trial tests whether replacing a standard chemo drug with Adcetris (brentuximab vedotin) can improve early tumor shrinkage in children with high-risk Hodgkin lymphoma. About 77 participants will receive two cycles of the new combo, followed by more chemo and possibly …

This phase 2 trial is testing whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can prevent Hodgkin lymphoma from coming back after a stem cell transplant. The study includes 62 patients with high-risk Hodgkin lymphoma that had returned or not responded to prior…

This early-phase pilot study is testing whether giving a PD-1 inhibitor (nivolumab or pembrolizumab) after CAR-T cell therapy can help people with relapsed or refractory classical Hodgkin lymphoma. The trial plans to enroll 10 adults whose cancer has not responded to at least thr…

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV), such as Hodgkin lymphoma and nasopharyngeal carcinoma. The treatment uses immune cells from healthy donors that are specially trained to attack EBV-infected cells. These cells are stored in a ban…

This study tests a modified chemotherapy regimen (based on a U.S. protocol) in 200 Chinese children and teens with newly diagnosed Hodgkin lymphoma. Depending on risk level, patients receive 4 to 6 cycles of chemotherapy, with or without low-dose radiation. The goal is to see if …

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This early-phase study tests a new way to calculate the dose of the chemotherapy drug melphalan for lymphoma patients about to receive a stem cell transplant. Instead of a fixed dose based on height and weight, researchers use a model that considers how previous patients processe…

This study tests a new drug called tislelizumab combined with chemotherapy for people whose Hodgkin lymphoma has returned or not responded to initial treatment. The goal is to see if this approach works as well as the standard intensive chemotherapy and stem cell transplant. Abou…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (ABVD) can improve cure rates for people with high-risk Hodgkin lymphoma. About 82 participants with untreated stage III or IV disease are enrolled. The Phase I part checks safety and side e…

This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a special receptor that targets the CD30 protein found on lymphoma cel…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …

This study tested a new drug combination (brentuximab vedotin plus standard chemotherapy) in 59 children with advanced, newly diagnosed Hodgkin lymphoma. The goal was to find the safest dose and see how well it shrinks tumors. Early results show many children achieved complete re…

This early-phase trial tests whether specially trained immune cells (T cells) that are made resistant to a tumor's defense chemical can safely fight relapsed EBV-positive lymphoma. Eight patients will receive two injections of these modified cells, 14 days apart, at increasing do…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This phase 2 trial is testing a combination of two drugs—nivolumab and brentuximab vedotin—in 46 older adults (60+) or those unable to receive standard chemotherapy for untreated Hodgkin lymphoma. The goal is to see if this immunotherapy-based approach can shrink or eliminate tum…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the metho…

This early-phase study tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can prevent the virus from causing problems in blood cancer patients after a transplant. About 34 donor-recipient pairs are taking part. The vaccine is given to the donor before stem c…

This study tests whether a tailored physical activity program can help lymphoma and breast cancer patients preserve their exercise ability, heart function, memory, and quality of life while undergoing cancer treatment. About 110 adults aged 18-85 with Hodgkin or non-Hodgkin lymph…

This study tests whether a special light therapy (transcranial photobiomodulation) used at home can help improve thinking and memory in adults who survived childhood leukemia or Hodgkin lymphoma. About 44 survivors will use a light device on their head while doing brain-training …

This study tests whether a shorter course of radiation (over 2-3 weeks instead of the usual 5-6 weeks) is safe for people with Hodgkin or Non-Hodgkin lymphoma that has returned or not responded to treatment. About 30 participants will receive different radiation doses to find the…

This study tests whether adding acupuncture to standard pain care can reduce the need for strong opioid painkillers in people with multiple myeloma, Hodgkin disease, or non-Hodgkin lymphoma who are getting high-dose chemotherapy. About 299 adults will be randomly assigned to rece…

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This study examines how social and genetic factors influence long-term health in 2000 adolescent and young adult survivors of Hodgkin or non-Hodgkin lymphoma. Researchers will collect blood samples and health information to identify risks for disease recurrence, other illnesses, …

This study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…

This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This study follows 21,000 adults newly diagnosed with non-Hodgkin lymphoma to learn which factors—like genetics, lifestyle, and treatment—affect survival and quality of life. Researchers will track health outcomes over time without providing a new treatment. The goal is to improv…

This study examines how common obstructive sleep apnea (OSA) is in adult survivors of Hodgkin lymphoma who received chest radiation. Researchers will compare 220 survivors to matched controls using sleep tests, brain scans, and heart assessments. The goal is to understand links b…

This study follows over 1,500 young adult survivors of childhood cancers like leukemia, brain tumors, and Hodgkin lymphoma to see how frailty—a measure of physical weakness and vulnerability—changes over five years. Researchers want to know if frailty can predict future chronic h…

This study is collecting real-world medical data from 400 elderly patients (age 60 and older) with Hodgkin lymphoma in China. Researchers will use this information to create a model that can better predict how the disease will progress and help doctors make more personalized trea…

This study looks at whether training doctors in communication skills can help lymphoma patients move from active treatment to survivorship. It involves 314 patients with Hodgkin's or Diffuse Large B-cell Lymphoma. The goal is to see if better conversations with their doctors impr…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…

This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…

This pilot study tests a new assessment tool called IA3-CP for cancer patients aged 65 and older. The tool gathers information on aging-related issues, mental health, health behaviors, and social factors to help doctors provide better, more personalized care. 35 participants are …

This study looks at whether a heart screening program is practical for people who survived Hodgkin's disease after chest radiation. Researchers will use echocardiograms and stress tests to find heart problems early and track risk factors. The goal is to improve care for 210 survi…

This study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…